Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fluzoparib Combination With Chemotherapy for Neoadjuvant Treatment of HRD-positive, HR+/HER2- Breast Cancer
NCT07162051Phase 2Completed
- Sponsor
- Xijing Hospital
- Start
- Mar 2023
- Primary completion
- Feb 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of fluzoparib in breast cancer, sponsored by Xijing Hospital. Primary endpoint: Residual tumor burden 0/I. Started Mar 2023; status: completed.
02
Drugs
fluzoparib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT07162051.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07162051.